Biological
CC312
CC312 is a biological therapy with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
2
50%
Ph early_phase_1
2
50%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
2(50.0%)
Phase 1Safety & dosage
2(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 12 (50.0%)
Phase 12 (50.0%)
Trials by Status
recruiting4100%
Recent Activity
4 active trials
Showing 4 of 4
recruitingearly_phase_1
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07193810
recruitingphase_1
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018
recruitingearly_phase_1
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960
recruitingphase_1
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911
Clinical Trials (4)
Showing 4 of 4 trials
NCT07193810Early Phase 1
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT06037018Phase 1
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06888960Early Phase 1
Safety Study of CC312 in Autoimmune Disease Patients
NCT07177911Phase 1
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4